HCW Biologics Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
HCWB$0.95-6.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity (Deficit)
| Stockholders’ Equity (Deficit) | |||||
|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity (Deficit) | |
| Balance, January 1, 2024 | 900,628 | $90 | $83,993,950 | $(70,532,323) | $13,461,717 |
| Issuance of Common Stock upon exercise of stock options | 336 | — | 2,444 | — | 2,444 |
| Issuance of Common Stock upon equity subscription | 44,643 | 5 | 2,500,001 | — | 2,500,006 |
| Issuance of Common Stock | 104,000 | 10 | 2,452,655 | — | 2,452,665 |
| Issuance of warrants | — | — | 4,465,588 | — | 4,465,588 |
| Exercise of pre-funded warrants | 63,925 | 6 | 250 | — | 256 |
| Issuance cost of Common Stock | — | — | (226,201) | — | (226,201) |
| Issuance costs of Common Stock warrants | — | — | (411,844) | — | (411,844) |
| Stock-based compensation | — | — | 1,009,011 | — | 1,009,011 |
| Net loss | — | — | — | (30,023,814) | (30,023,814) |
| Balance, December 31, 2024 | 1,113,532 | $111 | $93,785,854 | $(100,556,137) | $(6,770,172) |
| Issuance of Common Stock (1) | 727,447 | 73 | 4,496,855 | — | 4,496,928 |
| Issuance of pre-funded warrants | — | - | 4,207,718 | — | 4,207,718 |
| Issuance of Common Stock warrants | — | - | 14,948,620 | — | 14,948,620 |
| Exercise of pre-funded warrants | 513,140 | 51 | - | — | 51 |
| Issuance cost of Common Stock | — | - | (269,680) | — | (269,680) |
| Issuance cost of Common Stock warrants | — | - | (712,453) | — | (712,453) |
| Issuance cost of pre-funded warrants | — | - | (227,646) | — | (227,646) |
| Equity dividend to investor | — | - | (14,338,993) | — | (14,338,993) |
| Issuance of Common Stock upon exercise of stock options | 205 | - | 1,654 | — | 1,654 |
| Issuance of Common Stock to Square Gate | 9,616 | 1 | 149,999 | — | 150,000 |
| Issuance of Common Stock under Standby Equity Purchase Agreement | 600,000 | 60 | 2,804,845 | — | 2,804,905 |
| Issuance of Common Stock to extinguish restructured debt | 253,083 | 25 | 1,774,087 | — | 1,774,112 |
| Issuance of Common Stock warrants to extinguish restructured debt | — | - | 544,249 | — | 544,249 |
| Gain on conversion of debt with related parties | — | - | 3,346,562 | — | 3,346,562 |
| Stock-based compensation | — | - | 768,623 | — | 768,623 |
| Adjustment for reverse stock split | 62,789 | 7 | (7) | — | — |
| Net loss | — | - | - | (7,959,709) | (7,959,709) |
| Balance, December 31, 2025 | 3,279,812 | $328 | $111,280,287 | $(108,515,846) | $2,764,769 |
| (1) Represents the aggregate fair value of 1,704,447 shares of common stock, which includes 727,447 shares that have been issued and 977,000 shares held in abeyance (See Note 7 - Sale of Common Stock Warrants). | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.